18 studies found for:    "Muscular Dystrophies, Limb-Girdle"
Show Display Options
RSS Create an RSS feed from your search for:
"Muscular Dystrophies, Limb-Girdle"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Evaluation of Limb-Girdle Muscular Dystrophy
Conditions: Becker Muscular Dystrophy;   Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency);   Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency);   Limb-Girdle Muscular Dystrophy, Type 2I (FKRP-deficiency)
Intervention:
2 Recruiting Limb Girdle Muscular Dystrophy (LGMD) Natural History
Condition: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
Intervention:
3 Completed Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
Conditions: Limb Girdle Muscular Dystrophy Type 2C;   Gamma-sarcoglycanopathy
Intervention: Biological: AAV1-gamma-sarcoglycan vector injection
4 Unknown  Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy
Condition: Limb-Girdle Muscular Dystrophy
Intervention:
5 Completed Stem Cell Therapy in Limb Girdle Muscular Dystrophy
Condition: Limb Girdle Muscular Dystrophy
Intervention: Biological: Autologous bone marrow mononuclear cell transplantation
6 Recruiting Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I
Conditions: Becker Muscular Dystrophy;   Limb-Girdle Muscular Dystrophy Type 2I
Intervention:
7 Active, not recruiting Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA
Condition: Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
Intervention: Drug: scAAVrh74.tMCK.hSGCA
8 Completed Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)
Condition: Muscular Dystrophies
Interventions: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort;   Genetic: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
9 Completed Cardiac Outcome Measures in Children With Muscular Dystrophy
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb Girdle Muscular Dystrophy
Intervention:
10 Completed Cardiac Magnetic Resonance in Children With Muscular Dystrophy
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb Girdle Muscular Dystrophy
Intervention:
11 Recruiting Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb Girdle Muscular Dystrophy
Intervention: Drug: Coenzyme Q10 and Lisinopril
12 Recruiting Molecular Analysis of Patients With Neuromuscular Disease
Conditions: Limb-girdle Muscular Dystrophy;   Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Facioscapulohumeral Muscular Dystrophy
Intervention:
13 Completed Study Evaluating MYO-029 in Adult Muscular Dystrophy
Conditions: Becker Muscular Dystrophy;   Facioscapulohumeral Muscular Dystrophy;   Limb-Girdle Muscular Dystrophy
Intervention: Drug: MYO-029
14 Completed Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
Conditions: Muscular Dystrophies;   Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy;   Limb-Girdle Muscular Dystrophy
Intervention: Other: Retrograde high pressure transvenous perfusion with normal saline
15 Active, not recruiting Clinical Outcome Study for Dysferlinopathy
Conditions: Dysferlinopathy;   LGMD2B;   Miyoshi Myopathy
Intervention:
16 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
17 Recruiting Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin
Condition: Dysferlinopathy
Intervention: Drug: Bortezomib
18 Completed Deflazacort in Dysferlinopathies
Conditions: LGMD2B;   Miyoshi Myopathy;   Dysferlinopathy
Interventions: Drug: deflazacort;   Drug: placebo

Indicates status has not been verified in more than two years